Compare MHD & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHD | VALN |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.8M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | MHD | VALN |
|---|---|---|
| Price | $11.61 | $5.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 281.0K | 23.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.99 | $4.75 |
| 52 Week High | $12.08 | $12.25 |
| Indicator | MHD | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | N/A |
| Support Level | $11.40 | N/A |
| Resistance Level | $11.86 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 58.31 | 0.00 |
Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.